Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001213900-15-004466
Filing Date
2015-06-15
Accepted
2015-06-15 06:57:01
Documents
8
Period of Report
2014-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO ANNUAL REPORT f10k2014a1_endonovothera.htm 10-K/A 33905
2 GRAPHIC image_001.jpg GRAPHIC 6312
  Complete submission text file 0001213900-15-004466.txt   2682731

Data Files

Seq Description Document Type Size
3 XBRL INSTANCE FILE endv-20141231.xml EX-101.INS 292229
4 XBRL SCHEMA FILE endv-20141231.xsd EX-101.SCH 29660
5 XBRL CALCULATION FILE endv-20141231_cal.xml EX-101.CAL 26597
6 XBRL DEFINITION FILE endv-20141231_def.xml EX-101.DEF 94452
7 XBRL LABEL FILE endv-20141231_lab.xml EX-101.LAB 266703
8 XBRL PRESENTATION FILE endv-20141231_pre.xml EX-101.PRE 182065
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

EIN.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 333-176954 | Film No.: 15930168
SIC: 2834 Pharmaceutical Preparations